Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MyoScience Tissue Remodeling Device · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MyoScience Tissue Remodeling Device | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MyoScience Tissue Remodeling Device | DEVICE | Percutaneous treatment with the MyoScience device |
Inclusion Criteria: * The subject must be a female 30 to 70 years of age. * The subject must have a clinical examination prior to treatment including assessment of hyperdynamic line severity. * The subject must have a wrinkle rating of at least "1" at rest in one or more of the following treatment ...
The MyoScience Tissue Remodeling Device is an investigational device being studied for facial rejuvenation, specifically for the treatment of facial rhytides, which are wrinkles or fine lines on the face. It is currently in Phase 1 clinical development.
The MyoScience Tissue Remodeling Device is being developed by Pacira BioSciences, Inc., a company traded on the NASDAQ under the ticker symbol PCRX. The device is currently in Phase 1 clinical development for facial rhytides.
The MyoScience Tissue Remodeling Device is in Phase 1 clinical development. It is an investigational device and has not been approved by the FDA. One Phase 1 clinical trial for the device has been completed.
The MyoScience Tissue Remodeling Device has one completed clinical trial, identified as NCT00842062, titled 'Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation.' This Phase 1 study enrolled 380 female participants aged 30 years and older in the United States.
The MyoScience Tissue Remodeling Device is not FDA approved. It is an investigational device currently in Phase 1 clinical development for facial rhytides. A Phase 1 clinical trial has been completed, but the device has not yet received regulatory approval.